Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Trial Transparency To Move Up A Notch In UK

HRA To Build Sanctions Into Its Study Approvals Process

Executive Summary

The UK Health Research Authority has adopted a new strategy to give more teeth to its statutory objective of driving improvements in research transparency.

You may also be interested in...



UK To Reveal How Sponsors Are Performing On Trial Transparency Expectations

The UK is tightening its approach to enforcing best practices in clinical trial transparency.

UK To Up Transparency By ‘Auto Registering’ Trials

The UK says its initiative to unilaterally register clinical trials when they are given a research ethics committee approval will make it easier for trial sponsors to comply with their transparency requirements.

New UK System Will Check Trial Sponsors Report Study Results

The UK has started monitoring whether clinical trial sponsors are fulfilling responsibilities to make their research open and transparent.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142637

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel